Neurodegeneration collaboration news spotlighting a company announcement merging a proprietary research platform with an undisclosed therapeutic candidate; open for partnership insights.
Key Takeaways
- BioArctic received a USD 30 million upfront payment for the collaboration
- BioArctic can receive up to USD 770 million in additional milestone payments
- Lilly will lead global development and commercialization of the combined brain-targeted drug